{"transactions":[{"id":1451854,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":88890,"kind":"person","name":"GRINT PAUL C","position":1,"cik":"0001236548","reported_name":"GRINT PAUL C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-18T21:27:33.000Z","date":"2024-07-16","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest on the earlier of July 16, 2025 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date."}],"balance_after":30000,"derivative":{"exercise_price":1.54,"expiration_date":"2031-07-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-084674","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017024084674/ownership.xml","form_type":"4"}},{"id":1836440,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":88890,"kind":"person","name":"GRINT PAUL C","position":1,"cik":"0001236548","reported_name":"GRINT PAUL C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-07-06T01:12:56.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest on the earlier of June 30, 2024 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date."}],"balance_after":6667,"derivative":{"exercise_price":3.61,"expiration_date":"2033-06-30","underlying":"Common Stock","underlying_shares":6667},"source":{"system":"sec-edgar","filing":"0000950170-23-031852","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017023031852/ownership.xml","form_type":"4"}},{"id":2220221,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":88890,"kind":"person","name":"GRINT PAUL C","position":1,"cik":"0001236548","reported_name":"GRINT PAUL C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-29T01:00:30.000Z","date":"2022-06-24","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This entire stock option grant will vest 100% in a single tranche on the earlier of June 24, 2023 or the day prior to the next annual meeting of stockholders."}],"balance_after":40000,"derivative":{"exercise_price":0.81,"expiration_date":"2029-06-24","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-22-039710","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000120919122039710/doc4.xml","form_type":"4"}},{"id":2651890,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":88890,"kind":"person","name":"GRINT PAUL C","position":1,"cik":"0001236548","reported_name":"GRINT PAUL C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-29T23:11:20.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":22677,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22677,"derivative":{"exercise_price":2.92,"exercise_date":"2022-06-25","expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":22677},"source":{"system":"sec-edgar","filing":"0001104659-21-086990","document":"tm2120992d3_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000110465921086990/tm2120992d3_4.xml","form_type":"4"}},{"id":2930279,"issuer":{"id":5838,"kind":"organization","name":"Inhibikase Therapeutics, Inc."},"owners":[{"id":88890,"kind":"person","name":"GRINT PAUL C","position":1,"cik":"0001236548","reported_name":"GRINT PAUL C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-12-30T02:53:05.000Z","date":"2020-12-22","kind":"grant","acquired":true,"shares":6825,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6825,"derivative":{"exercise_price":10,"exercise_date":"2021-12-22","expiration_date":"2030-12-22","underlying":"Common Stock","underlying_shares":6825},"source":{"system":"sec-edgar","filing":"0001104659-20-140310","document":"tm2039455d4_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000110465920140310/tm2039455d4_form4.xml","form_type":"4"}},{"id":4135423,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":88890,"kind":"person","name":"GRINT PAUL C","position":1,"cik":"0001236548","reported_name":"GRINT PAUL C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-12-12T23:14:30.000Z","date":"2017-12-08","kind":"grant","acquired":true,"shares":599,"price":0.62,"value":371.38,"ownership":{"direct":true},"footnotes":[{"field":"timeliness","element":"transactionTimeliness","label":"F1","text":"These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":599,"source":{"system":"sec-edgar","filing":"0001209191-17-065259","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000120919117065259/doc4.xml","form_type":"4"}},{"id":4213035,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":88890,"kind":"person","name":"GRINT PAUL C","position":1,"cik":"0001236548","reported_name":"GRINT PAUL C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-09-12T00:17:47.000Z","date":"2017-09-07","kind":"grant","acquired":true,"shares":285113,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the stock option shall vest and become exercisable on September 5, 2027, subject to earlier vesting upon the satisfaction of performance criteria."}],"balance_after":285113,"derivative":{"exercise_price":0.91,"expiration_date":"2027-09-06","underlying":"Common Stock","underlying_shares":285113},"source":{"system":"sec-edgar","filing":"0001209191-17-052308","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921114/000120919117052308/doc4.xml","form_type":"4"}},{"id":4213034,"issuer":{"id":6329,"kind":"organization","name":"Armata Pharmaceuticals, Inc."},"owners":[{"id":88890,"kind":"person","name":"GRINT PAUL C","position":1,"cik":"0001236548","reported_name":"GRINT PAUL C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-09-12T00:17:47.000Z","date":"2017-09-07","kind":"grant","acquired":true,"shares":190076,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option vest on September 7, 2018.  The remainder of the shares vest in equal monthly installments thereafter over the next three years."}],"balance_after":190076,"derivative":{"exercise_price":0.91,"expiration_date":"2027-09-06","underlying":"Common Stock","underlying_shares":190076},"source":{"system":"sec-edgar","filing":"0001209191-17-052308","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921114/000120919117052308/doc4.xml","form_type":"4"}},{"id":4427456,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":88890,"kind":"person","name":"GRINT PAUL C","position":1,"cik":"0001236548","reported_name":"GRINT PAUL C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-23T17:21:28.000Z","date":"2017-02-15","kind":"grant","acquired":true,"shares":410000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares vest on January 1, 2018 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on January 1, 2021."}],"balance_after":410000,"derivative":{"exercise_price":1.2,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":410000},"source":{"system":"sec-edgar","filing":"0001209191-17-013896","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236548/000120919117013896/doc4.xml","form_type":"4"}},{"id":4473314,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":88890,"kind":"person","name":"GRINT PAUL C","position":1,"cik":"0001236548","reported_name":"GRINT PAUL C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-01T17:10:45.000Z","date":"2017-01-30","kind":"grant","acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On February 4, 2016, the reporting person was granted an option to purchase 130,000 shares of common stock. The option vests only upon achievement of a performance-based milestone. The performance criteria were met on January 30, 2017, resulting in vesting of the option. Upon achievement of the milestone, fifty percent of the shares immediately vest with the remaining shares vesting over the 24 month period following the vesting commencement date, subject to the reporting person's continuous service to Regulus."}],"balance_after":130000,"derivative":{"exercise_price":6.35,"exercise_date":"2017-01-30","expiration_date":"2026-02-03","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001209191-17-006791","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236548/000120919117006791/doc4.xml","form_type":"4"}},{"id":4582488,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":88890,"kind":"person","name":"GRINT PAUL C","position":1,"cik":"0001236548","reported_name":"GRINT PAUL C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-10-07T17:02:16.000Z","date":"2016-10-05","kind":"grant","acquired":true,"shares":186640,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares vest on October 5, 2017 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that\nthe option is fully vested on October 5, 2021."}],"balance_after":186640,"derivative":{"exercise_price":3.52,"expiration_date":"2026-10-04","underlying":"Common Stock","underlying_shares":186640},"source":{"system":"sec-edgar","filing":"0001209191-16-145418","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236548/000120919116145418/doc4.xml","form_type":"4"}}]}